FlyteHealth
Virtual-first cardiometabolic solution for obesity and related conditions (prediabetes/diabetes, hypertension, hyperlipidemia). Uses multidisciplinary care, precision pharmacotherapy, and digital engagement.
Access model
Mostly via employers, payers, health systems, and PBMs; some direct patient pathways through sponsored programs
Editorial note
B2B-heavy model; less consumer-transparent than D2C telehealth brands.
Coverage and cost
Usually via employer or health-plan benefit designs
Not transparently public for consumers; sponsor/employer pricing varies
Not publicly emphasized; focuses on GLP-1 and non-GLP-1 therapy plus medication-management partnerships
Market signals
Evidence and positioning
Company reports 13–16% average weight loss at 12 months. Milliman analysis of the Connecticut pilot found 86% adherence among new GLP-1 users and up to $1.2M first-year cost avoidance.
This is the lower dB's current read on FlyteHealth's pricing posture, insurance story, medication posture, and evidence signaling.
Source References
6 public references used in this profile. Links open in a new tab for quick verification.
Pricing, insurance coverage, medication availability, and eligibility can change quickly. Verify current details directly with the provider before starting or switching care.